Pfizer, Moderna get EU nod for boosting mRNA COVID-19 vaccine output


The Delpharm-operated site will help provide up to 51 million additional doses of Comirnaty in 2021, the EMA said.The regulator also said it had approved a new manufacturing line at BioNTech's site at Marburg in Germany, which would help boost capacity for the vaccine's active substance by about 410 million doses this year.

Europe's medicines regulator has approved additional manufacturing sites for mRNA-based coronavirus vaccines developed by Pfizer-BioNTech and Moderna to help boost production amid a resurgence in infections.

The European Medicines Agency (EMA) said https://www.ema.europa.eu/en/news/increase-vaccine-manufacturing-capacity-covid-19-vaccines-biontech-pfizer-moderna on Tuesday its human medicines committee had approved a site at Saint Remy sur Avre in France for making the Pfizer-BioNTech vaccine, Comirnaty.

The Delpharm-operated site will help provide up to 51 million additional doses of Comirnaty in 2021, the EMA said.

The regulator also said it had approved a new manufacturing line at BioNTech's site at Marburg in Germany, which would help boost capacity for the vaccine's active substance by about 410 million doses this year.

The European Union has been trying to boost and protect supplies after a rocky start to its vaccination campaign by bringing more facilities online and paying more https://www.reuters.com/world/europe/tougher-terms-why-eu-is-paying-more-new-covid-shots-2021-08-03 for new COVID shots.

The EMA also gave its go-ahead for an additional site at Bloomington, Indiana in the United States for Moderna's vaccine and several other locations involved in testing and packaging.

The Bloomington site is operated by contract drug manufacturer Catalent Inc.

The recommendations do not require a decision by the European Commission and the sites can become operational immediately, the EMA said.- Reuters

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Pfizer , Moderna , Biontech , vaccine , manufacturing , Europe , regulator ,

   

Next In Business News

Bank stocks stay positive amid negative market breadth
Budget 2022 to set tone for ringgit
Moody’s Analytics upbeat on AsiaPac, including Malaysia as travel curbs ease, stronger domestic demand
Strong demand for Agrobank’s first RM500m Sukuk
Ringgit opens higher amid caution over inflation
CIMB kickstarts week-long virtual customer appreciation event
CIMB inks landmark RM2.45b SLD transaction with Standard Chartered
Digital investment app MYTHEO launches ESG-themed portfolio
Fed to wait until 2023 to raise rates, but there is risk of earlier hike
Bursa extends lead as bank, energy rally continues

Others Also Read


Vouchers